1
|
Zeng F, Li S, Yang G, Luo Y, Qi T, Liang Y, Yang T, Zhang L, Wang R, Zhu L, Li H, Xu X. Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis. Acta Pharm Sin B 2020; 11:S2211-3835(20)30759-0. [PMID: 33078092 PMCID: PMC7558257 DOI: 10.1016/j.apsb.2020.10.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Revised: 09/17/2020] [Accepted: 09/28/2020] [Indexed: 01/15/2023] Open
Abstract
Human dihydroorotate dehydrogenase (DHODH) is a viable target for the development of therapeutics to treat cancer and immunological diseases, such as rheumatoid arthritis (RA), psoriasis and multiple sclerosis (MS). Herein, a series of acrylamide-based novel DHODH inhibitors as potential RA treatment agents were designed and synthesized. 2-Acrylamidobenzoic acid analog 11 was identified as the lead compound for structure-activity relationship (SAR) studies. The replacement of the phenyl group with naphthyl moieties improved inhibitory activity significantly to double-digit nanomolar range. Further structure optimization revealed that an acrylamide with small hydrophobic groups (Me, Cl or Br) at the 2-position was preferred. Moreover, adding a fluoro atom at the 5-position of the benzoic acid enhanced the potency. The optimization efforts led to potent compounds 42 and 53‒55 with IC50 values of 41, 44, 32, and 42 nmol/L, respectively. The most potent compound 54 also displayed favorable pharmacokinetic (PK) profiles and encouraging in vivo anti-arthritic effects in a dose-dependent manner.
Collapse
Key Words
- AML, acute myeloid leukemia
- Acrylamide derivatives
- BPO, benzoyl peroxide
- CIA, collagen-induced arthritis
- DCE, 1,2-dichloroethane
- DCM, dichloromethane
- DHODH
- DHODH inhibitors
- DHODH, dihydroorotate dehydrogenase
- DMAP, 4-dimethylaminopyridine
- DMARDs, disease-modifying antirheumatic drugs
- DMF, N,N-dimethylformamide
- DMSO, dimethyl sulfoxide
- De novo pyrimidine biosynthesis
- EA, ethyl acetate
- FMN, flavin mononucleotide
- HPLC, high performance liquid chromatography
- HRMS, high-resolution mass spectrometry
- IBD, inflammatory bowel disease
- LAH, lithium aluminium hydride
- LCMS, liquid chromatography mass spectrometry
- MS, multiple sclerosis
- MeOH, methanol
- NBS, N-bromosuccinimide
- NCS, N-chlorosuccinimide
- NSAIDs, non-steroidal anti-inflammatory drugs
- PDA, photodiode array detector
- PE, petroleum ether
- PK, pharmacokinetic
- PhMe, toluene
- RA, rheumatoid arthritis
- Rheumatoid arthritis
- SEL, systemic lupus erythematosus
- TEA, triethylamine
- TFA, trifluoroacetic acid
- THF, tetrahydrofuran
- TsCl, tosyl chloride
Collapse
Affiliation(s)
- Fanxun Zeng
- Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China
| | - Shiliang Li
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China
| | - Guantian Yang
- Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China
| | - Yating Luo
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China
| | - Tiantian Qi
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China
| | - Yingfan Liang
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China
| | - Tingyuan Yang
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China
| | - Letian Zhang
- Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China
| | - Rui Wang
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China
| | - Lili Zhu
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China
| | - Honglin Li
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China
| | - Xiaoyong Xu
- Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China
| |
Collapse
|